IDELVION offers powerful bleed protection

IN PROPHYLAXIS: IDELVION delivers zero bleeds regardless of dosing schedule

When dosed every 7 or 14 days, IDELVION had a zero median annualized spontaneous bleeding rate (AsBR).

When dosed at 14 days, IDELVION had an interquartile range, or IQR, of 0 to 1 bleed (IQR at 7 days was 0 to 0). IQR looks at the middle 50% of people in a clinical study and is used as a more accurate measure of expected range.

Hemophilia B patient John smiling in his police officer uniform

Since I've been infusing with IDELVION, I've had no bleeds.

-John, on the bleed protection IDELVION gives him

Watch John's story Watch John's story

ON DEMAND: A single dose effectively treats bleeds and offers extended protection—high and sustained Factor IX (FIX) levels for more than 14 days1

14-day dosing with high-level protection

A majority of bleeds resolved within 1–2 infusions:

  • 94% of bleeds resolved within 1 infusion
  • 99% of bleeds resolved within 1–2 infusions

IN SURGERY: IDELVION offers effective bleed protection

of rated surgeries were graded as “excellent” or “good” for bleed control three days after surgery

Hemophilia B patient Tony standing outdoors

I switched to IDELVION because it offered me greater protection. Before surgery, we had several conversations to decide the right dosing.

-Tony, on switching to IDELVION and having ankle replacement surgery

Watch Tony's story Watch Tony's story
21% FIX trough levels

See what Factor IX levels with 14-day dosing look like

Explore FIX levels
Sign up for IDELVION icon

Is it time for a Factor IX switch? Get the information you need

Sign up here

*Average FIX levels with 7-day dosing over 92 weeks in clincal trials.

References: 1. Santagostino E, Negrier C, Klamroth R, et al. Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients. Blood. doi:10.1182/blood-2012-05-429688. 2. Data on file. Available from CSL Behring as DOF IDL-002.

You are now leaving the current website.

Do you want to continue?

No Yes